BACKGROUND: Repeated exposure to intermittent normobaric hypoxia improves exercise tolerance in cardiac patients. Little is known on the effects of intermittent normobaric hypoxia-hyperoxia exposure in coronary artery disease (CAD) patients (New York Heart Association II-III). HYPOTHESIS: IHHT improves exercise tolerance, cardiometabolic profile, and quality of life in CAD patients. METHODS: The study design was a nonrandomized, controlled, before-and-after trial. Forty-six CAD patients volunteered to take part in the study: a group of 27 patients undertook the intermittent hypoxia (O2 at 10%)-hyperoxia (O2 at 30%) training (IHHT), whereas a control group (CTRL) of 19 patients, who already completed an 8-week standard cardiac rehabilitation program, was allocated to sham-IHHT treatment (breathing room air, O2 at 21%). Exercise performance, blood and metabolic profiles, and quality of life (Seattle Angina Questionnaire [SAQ]) were measured before and after in the IHHT group (IHHG) and sham-IHHT in the CTRL group. RESULTS: The IHHG showed improved exercise capacity, reduced systolic and diastolic blood pressures, enhanced left ventricle ejection fraction, and reduced glycemia, but only at 1-month follow-up. Angina as a reason to stop exercising was significantly reduced after treatment and at 1-month follow-up. The IHHT SAQ profile was improved in the IHHG and not significantly different to the CTRL group after standard rehabilitation. The IHHG was also compared to the CTRL group at 1-month follow-up, and no differences were found. CONCLUSIONS: In CAD patients, an IHHT program is associated with improved exercise tolerance, healthier risks factors profile, and a better quality of life. Our study also suggests that IHHT is as effective as an 8-week standard rehabilitation program.
BACKGROUND: Repeated exposure to intermittent normobaric hypoxia improves exercise tolerance in cardiac patients. Little is known on the effects of intermittent normobaric hypoxia-hyperoxia exposure in coronary artery disease (CAD) patients (New York Heart Association II-III). HYPOTHESIS: IHHT improves exercise tolerance, cardiometabolic profile, and quality of life in CAD patients. METHODS: The study design was a nonrandomized, controlled, before-and-after trial. Forty-six CAD patients volunteered to take part in the study: a group of 27 patients undertook the intermittent hypoxia (O2 at 10%)-hyperoxia (O2 at 30%) training (IHHT), whereas a control group (CTRL) of 19 patients, who already completed an 8-week standard cardiac rehabilitation program, was allocated to sham-IHHT treatment (breathing room air, O2 at 21%). Exercise performance, blood and metabolic profiles, and quality of life (Seattle Angina Questionnaire [SAQ]) were measured before and after in the IHHT group (IHHG) and sham-IHHT in the CTRL group. RESULTS: The IHHG showed improved exercise capacity, reduced systolic and diastolic blood pressures, enhanced left ventricle ejection fraction, and reduced glycemia, but only at 1-month follow-up. Angina as a reason to stop exercising was significantly reduced after treatment and at 1-month follow-up. The IHHT SAQ profile was improved in the IHHG and not significantly different to the CTRL group after standard rehabilitation. The IHHG was also compared to the CTRL group at 1-month follow-up, and no differences were found. CONCLUSIONS: In CAD patients, an IHHT program is associated with improved exercise tolerance, healthier risks factors profile, and a better quality of life. Our study also suggests that IHHT is as effective as an 8-week standard rehabilitation program.
Authors: Gerald F Fletcher; Philip A Ades; Paul Kligfield; Ross Arena; Gary J Balady; Vera A Bittner; Lola A Coke; Jerome L Fleg; Daniel E Forman; Thomas C Gerber; Martha Gulati; Kushal Madan; Jonathan Rhodes; Paul D Thompson; Mark A Williams Journal: Circulation Date: 2013-07-22 Impact factor: 29.690
Authors: Laura F DeFina; William L Haskell; Benjamin L Willis; Carolyn E Barlow; Carrie E Finley; Benjamin D Levine; Kenneth H Cooper Journal: Prog Cardiovasc Dis Date: 2014-09-28 Impact factor: 8.194
Authors: T G Sazontova; O S Glazachev; A V Bolotova; E N Dudnik; N V Striapko; I V Bedareva; N A Anchishkina; Iu V Arkhipenko Journal: Ross Fiziol Zh Im I M Sechenova Date: 2012-06
Authors: Martin Burtscher; Otmar Pachinger; Igor Ehrenbourg; Günther Mitterbauer; Martin Faulhaber; Reinhard Pühringer; Elena Tkatchouk Journal: Int J Cardiol Date: 2004-08 Impact factor: 4.164
Authors: Valeriy B Shatilo; Oleg V Korkushko; Vadim A Ischuk; H Fred Downey; Tatiana V Serebrovskaya Journal: High Alt Med Biol Date: 2008 Impact factor: 1.981
Authors: Tobias Duennwald; Luciano Bernardi; Daniel Gordin; Anna Sandelin; Anna Syreeni; Christopher Fogarty; Janne P Kytö; Hannes Gatterer; Markku Lehto; Sohvi Hörkkö; Carol Forsblom; Martin Burtscher; Per-Henrik Groop Journal: Diabetes Date: 2013-06-03 Impact factor: 9.461
Authors: Robert T Mallet; Eugenia B Manukhina; Steven Shea Ruelas; James L Caffrey; H Fred Downey Journal: Am J Physiol Heart Circ Physiol Date: 2018-04-13 Impact factor: 4.733
Authors: Oleg S Glazachev; Svetlana Yu Kryzhanovskaya; Maxim A Zapara; Elena N Dudnik; Vlada G Samartseva; Davide Susta Journal: Curr Cardiol Rev Date: 2021
Authors: Kusal K Das; Saeed M Yendigeri; Bheemshetty S Patil; Ishwar B Bagoji; R Chandramouli Reddy; Shrilaxmi Bagali; M S Biradar; Sikha Saha Journal: Indian J Pharmacol Date: 2018 Jul-Aug Impact factor: 1.200
Authors: Irina A Mandel; Yuri K Podoksenov; Irina V Suhodolo; Darya A An; Sergey L Mikheev; Andrey Yu Podoksenov; Yulia S Svirko; Anna M Gusakova; Vladimir M Shipulin; Andrey G Yavorovskiy Journal: Int J Mol Sci Date: 2020-07-27 Impact factor: 5.923
Authors: Denis S Tuter; Philippe Y Kopylov; Abram L Syrkin; Oleg S Glazachev; Roman N Komarov; Andrei I Katkov; Ljudmila P Severova; Ekaterina V Ivanova; Young Zhang; Hugo Saner Journal: Open Heart Date: 2018-11-10
Authors: Zoya O Serebrovska; Tetiana V Serebrovska; Viktor A Kholin; Lesya V Tumanovska; Angela M Shysh; Denis A Pashevin; Sergii V Goncharov; Dmytro Stroy; Oksana N Grib; Valeriy B Shatylo; Natalia Yu Bachinskaya; Egor Egorov; Lei Xi; Victor E Dosenko Journal: Int J Mol Sci Date: 2019-10-30 Impact factor: 5.923